Department of Microbiology & Immunology
Christina Voelkel-Johnson has not added Biography.
If you are Christina Voelkel-Johnson and would like to personalize this page please email our Author Liaison for assistance.
Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL.
Cancer gene therapy Feb, 2002 | Pubmed ID: 11857034
Doxorubicin pretreatment sensitizes prostate cancer cell lines to TRAIL induced apoptosis which correlates with the loss of c-FLIP expression.
Cancer biology & therapy Sep-Oct, 2002 | Pubmed ID: 12496481
An antibody against DR4 (TRAIL-R1) in combination with doxorubicin selectively kills malignant but not normal prostate cells.
Cancer biology & therapy May-Jun, 2003 | Pubmed ID: 12878867
Enhanced apoptosis of glioma cell lines is achieved by co-delivering FasL-GFP and TRAIL with a complex Ad5 vector.
Cancer gene therapy Nov, 2003 | Pubmed ID: 14605667
In vitro efficacy of Fas ligand gene therapy for the treatment of bladder cancer.
Cancer gene therapy Jan, 2005 | Pubmed ID: 15514684
Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancer xenografts.
BMC cancer Jan, 2005 | Pubmed ID: 15638938
Resistance to TRAIL is associated with defects in ceramide signaling that can be overcome by exogenous C6-ceramide without requiring down-regulation of cellular FLICE inhibitory protein.
Molecular cancer therapeutics Sep, 2005 | Pubmed ID: 16170023
Targeting the short form of cFLIP by RNA interference is sufficient to enhance TRAIL sensitivity in PC3 prostate carcinoma cells.
Cancer biology & therapy Dec, 2006 | Pubmed ID: 17106251
Illuminating TRAIL gene therapy.
Cancer biology & therapy Nov, 2006 | Pubmed ID: 17204862
Doxorubicin generates a proapoptotic phenotype by phosphorylation of elongation factor 2.
Free radical biology & medicine Nov, 2007 | Pubmed ID: 17893044
Transformation, translation and TRAIL: an unexpected intersection.
Cytokine & growth factor reviews Apr, 2008 | Pubmed ID: 18353705
径组合疗法: 最近的事态发展和潜在的陷阱。
Cancer biology & therapy Jan, 2009 | Pubmed ID: 19127121
MDA-7/IL-24-induced cell killing in malignant renal carcinoma cells occurs by a ceramide/CD95/PERK-dependent mechanism.
Molecular cancer therapeutics May, 2009 | Pubmed ID: 19417161
Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and -independent mechanisms.
Molecular pharmacology Aug, 2009 | Pubmed ID: 19483104
The role of protein synthesis in cell cycling and cancer.
Molecular oncology Dec, 2009 | Pubmed ID: 19546037
Oxidative stress and lymphocyte persistence: implications in immunotherapy.
Advances in cancer research , 2009 | Pubmed ID: 19595310
Oxidative stress sensitizes bladder cancer cells to TRAIL mediated apoptosis by down-regulating anti-apoptotic proteins.
The Journal of urology Sep, 2009 | Pubmed ID: 19625063
Inhibition of superoxide generation upon T-cell receptor engagement rescues Mart-1(27-35)-reactive T cells from activation-induced cell death.
Cancer research Aug, 2009 | Pubmed ID: 19638595
Polymer-enhanced adenoviral transduction of CAR-negative bladder cancer cells.
Molecular pharmaceutics Sep-Oct, 2009 | Pubmed ID: 19655763
17-allylamino-17-demethoxygeldanamycin and MEK1/2 inhibitors kill GI tumor cells via Ca2+-dependent suppression of GRP78/BiP and induction of ceramide and reactive oxygen species.
Molecular cancer therapeutics May, 2010 | Pubmed ID: 20442308
Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2+)-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway.
Cancer research Aug, 2010 | Pubmed ID: 20631069
Sorafenib activates CD95 and promotes autophagy and cell death via Src family kinases in gastrointestinal tumor cells.
Molecular cancer therapeutics Aug, 2010 | Pubmed ID: 20682655
Adenoviral infectivity of exfoliated viable cells in urine: implications for the detection of bladder cancer.
BMC cancer , 2011 | Pubmed ID: 21569442
T cells expanded in presence of IL-15 exhibit increased antioxidant capacity and innate effector molecules.
Cytokine Aug, 2011 | Pubmed ID: 21602054
TRAIL-mediated signaling in prostate, bladder and renal cancer.
Nature reviews. Urology Aug, 2011 | Pubmed ID: 21670755
Histone deacetylase inhibitors restore cell surface expression of the coxsackie adenovirus receptor and enhance CMV promoter activity in castration-resistant prostate cancer cells.
Prostate cancer , 2012 | Pubmed ID: 22288017
Inner ear supporting cells protect hair cells by secreting HSP70.
The Journal of clinical investigation Aug, 2013 | Pubmed ID: 23863716
Targeting sphingosine kinase induces apoptosis and tumor regression for KSHV-associated primary effusion lymphoma.
Molecular cancer therapeutics Oct, 2013 | Pubmed ID: 24140934
关于 JoVE
版权所属 © 2024 MyJoVE 公司版权所有,本公司不涉及任何医疗业务和医疗服务。